Advancing RNAi-based therapeutics to transform the treatment of human diseases.

At Marina Biotech we are focused on realizing the potential of RNAi-based therapeutics through the development of multiple broad-based, state-of-the-art drug discovery platforms built upon industry leading expertise in RNA chemistry, microbiology and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics to treat critical unmet medical needs.

Therapeutic Platform

We are using multiple RNAi drug discovery engines, tkRNAi and tauRNAi, to develop cutting-edge, first-in-class therapeutics for diverse and commercially valuable disease targets.Learn More

Upcoming Clinical Trial

Marina Biotech’s first therapeutic candidate, CEQ508 for the treatment of Familial Adenomatous Polyposis (FAP), is now recruiting. Learn More

Latest News & Events

Marina Biotech, Inc. at Biotech Showcase 2014
Wednesday, January 15, 2014, 4:15 pm PST Register


MDRNA has merged with Cequent Pharmaceuticals to become Marina Biotech - focused on accelerating RNAi-based therapeutics. Learn More

All Press Releases